Can steroids save lives in severe flu pneumonia? new trial aims to find out
NCT ID NCT07351500
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial will test whether adding low or moderate doses of the corticosteroid methylprednisolone to standard care can lower the death rate in adults with severe influenza pneumonia in the ICU. About 496 participants will be randomly assigned to receive either saline (placebo), low-dose, or moderate-dose methylprednisolone. The main goal is to see if the drug reduces deaths within 28 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Methylprednisolone (a corticosteroid drug)
- What this could lead to
- If it works, this could provide a clear treatment option to reduce deaths from severe influenza pneumonia.
- What could go wrong
- This is an early-stage trial with only 496 participants, and corticosteroids have previously been linked to higher mortality in some flu studies, so results may not be conclusive or positive.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Flu vaccine showdown: which shot protects seniors best?
- Can a simple breath test catch flu in High-HIV regions?
- Can a simple mask stop the flu? 2,000 volunteers put it to the test
- Can a stronger flu shot better protect seniors?
- Flu shot showdown: Cell-Grown vs recombinant vaccine put to the test
- New mRNA vaccine aims to outsmart flu by targeting its hidden parts